Indivior PLC (NASDAQ:INDV) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have been given an average recommendation of “Moderate Buy” by the seven analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $39.3333.

Several research analysts recently weighed in on INDV shares. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. HC Wainwright raised their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a research report on Wednesday, December 3rd. Northland Securities set a $50.00 target price on shares of Indivior in a report on Tuesday, January 20th. Finally, Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, March 2nd.

Indivior Stock Performance

NASDAQ:INDV opened at $32.27 on Wednesday. The stock’s fifty day moving average price is $34.11 and its two-hundred day moving average price is $30.39. The company has a market cap of $4.04 billion, a price-to-earnings ratio of 19.68 and a beta of 0.83. Indivior has a 52-week low of $8.64 and a 52-week high of $38.00.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The business had revenue of $358.00 million for the quarter, compared to analyst estimates of $305.62 million. On average, equities analysts predict that Indivior will post 1.22 EPS for the current fiscal year.

Insider Transactions at Indivior

In other Indivior news, Director Keith Humphreys purchased 775 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the purchase, the director directly owned 5,802 shares of the company’s stock, valued at $205,332.78. The trade was a 15.42% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Barbara Ryan acquired 775 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 1,963 shares of the company’s stock, valued at $69,470.57. This represents a 65.24% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 4,871 shares of company stock worth $172,385.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Oaktree Capital Management LP raised its position in Indivior by 2,241.6% during the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after acquiring an additional 246,776,273 shares in the last quarter. Divisadero Street Capital Management LP grew its position in shares of Indivior by 2,372.5% in the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after acquiring an additional 3,226,605 shares during the period. Fuller & Thaler Asset Management Inc. increased its stake in shares of Indivior by 101.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after purchasing an additional 3,201,639 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Indivior in the 4th quarter valued at about $82,687,000. Finally, Vanguard Group Inc. raised its holdings in shares of Indivior by 57.9% in the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock valued at $196,403,000 after purchasing an additional 2,008,078 shares during the period. 60.33% of the stock is currently owned by institutional investors.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.